Kit and method for detecting relative anticoagulant activity of low-molecular heparin in sample
Through kits and methods, through mixed incubation of samples with specific reagents and fitting linear functions, the problem of not being able to monitor the anticoagulation activity of low molecular heparin in the prior art is solved, and the rapid and accurate anticoagulation activity of low molecular heparin is achieved. Evaluation improves balance judgment and therapeutic effect of coagulation function.
Patent Information
- Application Number
- CN202411014673.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-15
AI Technical Summary
The anticoagulant activity of low molecular weight heparin cannot be effectively monitored in the prior art, especially the anticoagulant activity of daheparin sodium and enoxaparin sodium, which limits the comprehensive evaluation of coagulation function and the judgment of therapeutic effect.
Provide a kit and method to incubate samples with specific compositions of reagents 1 and reagent 2 and record the number of anticoagulation test seconds at different incubation times, fit a straight line function to judge the relative anticoagulation of low molecular weight heparin. Activity, assess its comprehensive anticoagulant activity against endogenous coagulation pathways and coagulation common pathways.
This method can quickly and accurately judge the relative anticoagulation activity of low molecular heparin in multiple samples, provide important theoretical and practical value, help evaluate the equilibrium state of coagulation function and improve treatment effect.
Smart Images

Figure CN118962161A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biological diagnosis, and particularly relates to a kit and a method for detecting the relative anticoagulant activity of low molecular weight heparin in a sample. Background Art
[0002] Coagulation function refers to the ability to change blood from a flowing state to a non-flowing gel state. In essence, it is the function of converting soluble fibrinogen in plasma into insoluble fibrin. In a narrow sense, coagulation function refers to the ability of the body to activate coagulation factors in a certain order to form an activated form when blood vessels are damaged, and finally activate coagulation factor X and coagulation factor II to generate thrombin, which converts fibrinogen into fibrin and promotes blood coagulation. In a broad sense, coagulation function also includes the procoagulant activity of platelets, the function of the anticoagulant system and the function of the fibrinolytic system.
[0003] Whether the coagulation function of the human body is normal and whether the human body is healthy, in theory, requires the coagulation system, anticoagulation system and fibrinolysis system in the human body to work together. A normal person maintains a balance between the three systems, that is, the balance between the procoagulant power of the coagulation system and the anticoagulant power of the anticoagulant system and fibrinolysis system. Therefore, a normal person will neither bleed nor develop thrombosis, and maintain a healthy state.
[0004] If blood vessels are damaged in the human body, or blood vessels and tissues are damaged during surgery, subendothelial collagen will be exposed to activate the endogenous coagulation pathway, and the release of tissue factor will activate the exogenous coagulation pathway. Due to the presence of coagulation factors and the platelets providing phospholipid surface to catalyze the activation of the coagulation factor waterfall, the coagulation system in the body will be activated, and the corresponding anticoagulation system will also be activated, such as the anticoagulant effect of antithrombin (AT or AT III) and the anticoagulant effect of the protein C system inactivating Va and VIIIa coagulation factors. Clinical doctors need to comprehensively judge the patient's coagulation function, including coagulation factor activity, protein C system (protein C and protein S), plasminogen and plasmin inhibitors and other indicators to use low molecular weight heparin. Low molecular weight heparin injected into the human body will also bind to AT, greatly enhancing the activity of AT and playing an anticoagulant role.
[0005] In clinical practice, when patients use low molecular weight heparin, their coagulation function shows a comprehensive coagulation function of platelet function, coagulation factors, anticoagulant system (AT and protein C system), and fibrinolytic system. Only when the forces of anticoagulation, procoagulant and fibrinolytic systems are balanced can the best treatment effect be guaranteed for patients. Therefore, detecting the activity of low molecular weight heparin as an anticoagulant factor in the patient's plasma can provide an important reference for evaluating the anticoagulant activity of the patient's plasma. However, because the patient's overall coagulation function is affected by the comprehensive effects of the anticoagulation system, coagulation system and fibrinolytic system, the patient's overall coagulation function cannot be judged based on the activity of low molecular weight heparin as one of the anticoagulant factors in the patient's plasma.
[0006] Regarding the anticoagulant drug monitoring of low molecular weight heparin in the existing technology, the "Consensus on Thrombosis and Bleeding Risk Monitoring" (first edition) of Wuhan Asia Heart Hospital clearly states that there is only one monitoring indicator for low molecular weight heparin: Anti-Xa. APTT has no reaction to low molecular weight heparin and cannot be used to monitor the anticoagulant activity of low molecular weight heparin (such as dalteparin sodium and enoxaparin sodium). Summary of the invention
[0007] In order to solve the above problems existing in the prior art, the present invention provides the following technical solutions.
[0008] The first aspect of the present invention provides a kit for detecting the relative anticoagulant activity of low molecular weight heparin in a sample, the kit comprising reagent one and reagent two, wherein:
[0009] The reagent 1 comprises the following components:
[0010] Activator: 20-100 mg / L;
[0011] Phospholipids: 0.5-2.0 g / L;
[0012] Stabilizer: 0.5~2.0g / L;
[0013] Buffer: 20~100mmol / L;
[0014] Reagent 2:
[0015] CaCL2 solution: 0.015~0.025mol / L.
[0016] The second aspect of the present invention provides a method for detecting the relative anticoagulant activity of low molecular weight heparin in a sample, the method comprising the following steps:
[0017] 1) adding at least two samples into a plurality of reaction cups respectively, and then adding reagents into each reaction cup and incubating them together;
[0018] Wherein, the incubation time of different reaction cups is at least three selected from 5min-30min;
[0019] 2) After the incubation is completed, reagent 2 is added to the reaction cup to trigger the coagulation process, and the time required for plasma coagulation is measured to obtain the anticoagulation test seconds under different incubation times;
[0020] 3) Construct a rectangular coordinate system with the incubation time as the horizontal axis and the anticoagulation test seconds as the vertical axis;
[0021] Mark the points of the different incubation times described in step 1) and the corresponding anticoagulation test seconds described in step 2) in the plane rectangular coordinate system, and fit the marked points into a straight line in the plane rectangular coordinate system;
[0022] If the function of the straight line y = kx + b R 2 >0.95, the relative anticoagulant activity of the low molecular weight heparins in the multiple samples is determined according to the k value of the linear function: the linear function with a larger k value corresponds to a sample with a higher anticoagulant activity of the low molecular weight heparin.
[0023] The kit for detecting the relative anticoagulant activity of low molecular weight heparin in a sample and the method for detecting the relative anticoagulant activity of low molecular weight heparin in a sample provided by the present invention can conveniently and quickly determine the relative anticoagulant activity of low molecular weight heparin in multiple samples containing low molecular weight heparin, and can evaluate the relative comprehensive anticoagulant activity of low molecular weight heparin on the intrinsic coagulation pathway and the common coagulation pathway (anti-IIa, anti-Xa, anti-IXa, anti-XIa, anti-XIIa, etc.) among multiple samples, which has important theoretical and practical value. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Schematic diagram of the straight line function obtained in Example 1.
[0025] Figure 2 Schematic diagram of the straight line function obtained in the reference example.
[0026] Figure 3 Schematic diagram of the straight line function obtained in Example 2.
[0027] Figure 4 Schematic diagram of the straight line function obtained in Example 3.
[0028] Figure 5 Schematic diagram of the straight line function obtained in Example 4.
[0029] Figure 6 This is a schematic diagram of the straight line function obtained in Example 5. DETAILED DESCRIPTION
[0030] To make the technical solution, purpose and advantages of the present invention clearer, the present invention is further described in detail below through specific implementation examples. It should be understood that the specific implementation methods described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0031] In the present invention, the term "low molecular weight heparin" refers to a general term for a class of heparins with lower molecular weight prepared by depolymerization of ordinary heparin, which is low molecular weight glucosamine sulfate with an average molecular weight of 4000-6000. According to the molecular weight, chain end structure and compound-bound salts, it can be divided into different commercial preparations, mainly including dalteparin sodium, enoxaparin sodium and nadroparin calcium.
[0032] In the present invention, the term "plasma coagulation" means that after the reagent components are added to the sample plasma, the coagulation factors in the plasma are transformed from the zymogen form to the activated state, and finally the fibrinogen is transformed into fibrin, so that the sample is transformed from a liquid state to a gel-like solid state.
[0033] The first aspect of the present invention provides a kit for detecting the relative anticoagulant activity of low molecular weight heparin in a sample, the kit comprising reagent one and reagent two, wherein:
[0034] The reagent 1 comprises the following components:
[0035] Activator: 20-100 mg / L;
[0036] Phospholipids: 0.5-2.0 g / L;
[0037] Stabilizer: 0.5~2.0g / L;
[0038] Buffer: 20~100mmol / L;
[0039] The above concentrations are all the final concentrations of the corresponding components in the reagent 1.
[0040] Reagent 2:
[0041] CaCL2 solution: 0.015~0.025mol / L.
[0042] Wherein, the activator may be at least one selected from kaolin, silica gel and ellagic acid, preferably ellagic acid.
[0043] The phospholipids can be cephalin derived from rabbit brain or bovine brain, or artificially synthesized phospholipids.
[0044] The stabilizer may be one or both of bovine serum albumin and polyethylene glycol with a molecular weight of 6000-20000.
[0045] The buffer may be a Tris-HCL buffer.
[0046] The kit may further include a preservative, and the final concentration of the preservative in the reagent 1 may be 0.5 to 1.0 g / L. The preservative may be, for example, proclin 300 and / or sodium azide.
[0047] According to the first aspect of the present invention, preferably, the kit comprises reagent 1 and reagent 2, wherein:
[0048] The following components in the reagent 1 can be:
[0049] Activator: The concentration of activator in reagent 1 is any one of 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 mg / L or a range between two thereof, for example, any one of 50-70 mg / L, 45-75 mg / L, 40-80 mg / L, 35-85 mg / L, 30-90 mg / L, 25-65 mg / L, 20-60 mg / L, 35-75 mg / L, 50-100 mg / L;
[0050] Phospholipids: the concentration in reagent 1 is any one of 0.5, 0.6, 0.7, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0 g / L or a range between two thereof, for example, any one of 1.0-1.4 g / L, 0.8-1.6 g / L, 0.7-1.8 g / L, 0.5-1.2 g / L, 0.6-1.6 g / L, 1.0-2.0 g / L, 1.2-1.8 g / L, 1.0-2.0 g / L;
[0051] Stabilizer: The concentration in reagent 1 is any one of 0.5, 0.6, 0.7, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0 g / L or a range between two thereof, for example, any one of 1.0-1.4 g / L, 0.8-1.6 g / L, 0.7-1.8 g / L, 0.5-1.2 g / L, 0.6-1.6 g / L, 1.0-2.0 g / L, 1.2-1.8 g / L, 1.0-2.0 g / L;
[0052] Buffer: The concentration in reagent 1 is any one of 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 mg / L or a range between two thereof, for example, any one of 50-70 mg / L, 45-75 mg / L, 40-80 mg / L, 35-85 mg / L, 30-90 mg / L, 25-65 mg / L, 20-60 mg / L, 35-75 mg / L, 50-100 mg / L;
[0053] Preservative: The concentration in reagent 1 is any one of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 g / L or a range between two of them, for example, any one of 0.5-0.7 g / L, 0.6-0.8 g / L, 0.7-1.0 g / L, 0.8-1.0 g / L, 0.6-0.9 g / L, 0.5-0.8 g / L, 0.6-1.0 g / L.
[0054] Reagent 2:
[0055] The concentration of the CaCL2 solution is a range between any one or two of 0.015mol / L, 0.016mol / L, 0.017mol / L, 0.018mol / L, 0.019mol / L, 0.020mol / L, 0.021mol / L, 0.022mol / L, 0.023mol / L, 0.024mol / L and 0.025mol / L, for example, any one of 0.018-0.021mol / L, 0.017-0.023mol / L, 0.016-0.024mol / L, 0.015-0.020mol / L, 0.016-0.021mol / L, 0.018-0.024mol / L, 0.019-0.023mol / L.
[0056] The above reagent 1 can be prepared by the following operation method:
[0057] According to the components and concentration requirements of the above reagent one, a buffer solution is first prepared, and then the activator, phospholipid, stabilizer and preservative are added to the buffer solution and mixed to obtain reagent one.
[0058] The second aspect of the present invention provides a method for detecting the relative anticoagulant activity of low molecular weight heparin in a sample, the method comprising the following steps:
[0059] 1) adding at least two samples to multiple reaction cups respectively, and then adding reagents to each reaction cup and incubating them together at a temperature of 35° C.-38° C., preferably 37° C.;
[0060] The incubation time of different reaction cups is at least three selected from 5 min-30 min; in each reaction cup, the volume ratio of the sample to the reagent 1 is 1:(1-3), such as any one of 1:1, 1:2 or 1:3 or a range between two, preferably 1:1;
[0061] 2) After the incubation is completed, reagent 2 is added to the reaction cup to trigger the coagulation process, and the time required for plasma coagulation is measured to obtain the anticoagulation test seconds under different incubation times;
[0062] Wherein, in each reaction cup, the volume ratio of the sample to the second reagent is 1:(1-3), such as any one of 1:1, 1:2 or 1:3 or a range between two thereof, preferably 1:1;
[0063] 3) Construct a rectangular coordinate system with the incubation time as the horizontal axis and the anticoagulation test seconds as the vertical axis;
[0064] Mark the points of the different incubation times described in step 1) and the corresponding anticoagulation test seconds described in step 2) in the plane rectangular coordinate system, and fit the marked points into a straight line in the plane rectangular coordinate system;
[0065] If the R of the straight line function y=kx+b 2 >0.95, the relative anticoagulant activity of the low molecular weight heparins in multiple samples can be judged according to the k value of the linear function (i.e., the slope of the linear function): the linear function with a larger k value corresponds to a sample with a higher anticoagulant activity of the low molecular weight heparin.
[0066] According to the second aspect of the present invention, the sample can be: plasma obtained by centrifugation after whole blood is collected from anticoagulation tubes for routine coagulation tests. The plasma collection standard refers to the "Expert Consensus on Quality Assurance of Routine Plasma Coagulation Tests".
[0067] According to the second aspect of the present invention, preferably, the different incubation times described in step 1) can be three; the three incubation times can preferably be at least two selected from the three ranges of 5min-10min, 10min-20min, and 20min-30min; for example, the three incubation times can be 5min, 15min and 25min, or 8min, 14min and 23min, or 6min, 12min and 26min, or 5min, 8min and 20min, or 12min, 18min and 22min, or 16min, 22min and 30min, or any combination of 12min, 18min and 22min.
[0068] According to the second aspect of the present invention, preferably, the different incubation times described in step 1) can be four; the four incubation times can preferably be at least two selected from the three ranges of 5min-10min, 10min-20min, and 20min-30min; for example, the four incubation times can be 10min, 15min, 20min and 30min, 5min, 8min, 16min and 22min, 6min, 9min, 17min and 23min, 7min, 12min, 18min and 24min, 6min, 13min, 19min and 25min, 8min, 19min, 21min and 26min, 9min, 16min, 22min and 29min, 6min, 9min, 12min and 18min, 13min, 19min, 25min and 28min, any combination of 5min, 8min, 24min and 29min.
[0069] According to the second aspect of the present invention, preferably, the different incubation times described in step 1) can be five or more; the five or more incubation times can preferably be at least two selected from the three ranges of 5min-10min, 10min-20min, and 20min-30min.
[0070] According to the second aspect of the present invention, when the R of the straight line function 2 When the value is >0.95, it means that after the low molecular weight heparin and antithrombin (AT) in the corresponding sample are combined, the low molecular weight heparin continues to inactivate the activated coagulation factors (coagulation factors XIIa, XIa, Xa, IXa, IIa) in the reaction system; the larger the slope of the linear function (k value), the more activated coagulation factors are inactivated by low molecular weight heparin anticoagulation per unit time; the smaller the slope of the linear function (k value), the less activated coagulation factors are inactivated by low molecular weight heparin anticoagulation per unit time. Therefore, the relative size of the anticoagulant activity of low molecular weight heparin in multiple samples can be judged according to the size of the slope of the linear function (k value).
[0071] According to the second aspect of the present invention, a fully automatic coagulation analyzer (eg, a product model ACL TOP 700 purchased from Werfen) may be used to perform the operations of step 1) and step 2).
[0072] The method for detecting the relative anticoagulant activity of low molecular weight heparin in a sample provided in the second aspect of the present invention is not directly intended to obtain the diagnosis result or health status of the same subject, nor can it directly derive the diagnosis result or health status of the disease. It only obtains the relative anticoagulant activity of an influencing factor (low molecular weight heparin) of the anticoagulant part of the plasma coagulation function of two or more samples. Therefore, it does not involve the diagnosis and treatment of the disease at all. If there is evidence that the method provided in the second aspect of the present invention may have some applications involving the diagnosis and treatment of the disease, the applicant may waive the requirement for this part of the application involving the diagnosis and treatment of the disease that has been proven by sufficient evidence and arguments of the opponent, and only retain the application of the part that does not involve the diagnosis and treatment of the disease.
[0073] The various reagents, materials, etc. used in the following examples, unless otherwise specified, are all products that can be obtained from commercial channels; the various tests and detection methods used in the following examples, unless otherwise specified, are all conventional tests and detection methods in the art and can be obtained from textbooks, reference books or academic journals.
[0074] Example 1
[0075] In this embodiment, the components and preparation method of the kit used to detect the anticoagulant activity of low molecular weight heparin in a sample are as follows:
[0076] Preparation of reagent 1:
[0077] Weigh 10.8g Tris into 800mL ultrapure water, stir evenly, adjust pH to 7.30 with HCL, and adjust the volume of buffer to 1000mL to obtain Tris-HCL buffer. Weigh 35mg ellagic acid and add it to the above buffer to make the final concentration of ellagic acid 35mg / L; then add 1.5g rabbit cephalin, 1.0g bovine serum albumin, 0.4g polyethylene glycol 6000, and add proclin300 to a final concentration of 0.8%.
[0078] Reagent 2: CaCL2 solution 0.024 mol / L.
[0079] In this embodiment, the samples used are plasma samples obtained by drawing blood 4 hours after subcutaneous injection of low molecular weight heparin (samples No. 1 and No. 2 are dalteparin sodium, and sample No. 3 is enoxaparin sodium) from patients who were known to be treated with low molecular weight heparin (samples No. 1 and No. 2 are dalteparin sodium, and sample No. 3 is enoxaparin sodium) and centrifuging the blood.
[0080] The specific operation of detecting the anticoagulant activity of low molecular weight heparin in the sample is as follows (the operation of samples No. 1, No. 2 and No. 3 is exactly the same):
[0081] 1) Using a fully automatic coagulation analyzer, 50 μL of sample plasma was automatically added to four reaction cups, and then 50 μL of the above reagents were added to each reaction cup, and the mixture was incubated at 37°C. The incubation time of the four reaction cups was set to 10 min, 15 min, 20 min, and 30 min, respectively;
[0082] 2) After the four reaction cups are incubated for the incubation time in step 1), 50 μL of the above reagent 2 is added to each of the four reaction cups to trigger the coagulation process, and the time required for plasma coagulation is measured and recorded to obtain the anticoagulation test seconds at different incubation times;
[0083] 3) Construct a rectangular coordinate system with the incubation time as the horizontal axis and the anticoagulation test seconds as the vertical axis;
[0084] The different incubation times in step 1) and the corresponding anticoagulation test seconds in step 2) are marked as points in the rectangular coordinate system of the plane, and are fitted into straight lines, respectively, as shown in FIG. Figure 1 shown.
[0085] like Figure 1 As shown in the figure, when the points of the incubation time of 10min, 15min, 20min, 30min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the linear function fitted by sample No. 1 is y=0.304x+26.2(R 2 =0.9968); the linear function of sample 2 is y=0.1846x+29.114(R 2 =0.0.9979); the linear function of sample 3 is y=0.508x+30.6(R 2 =0.9965).
[0086] It can be seen that when the points of the incubation time of 10min, 15min, 20min, 30min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the R values of the linear function fitted by samples 1, 2, and 3 are 2 The values all satisfy R 2 >0.95, so according to the size of k value (the k values of the fitting straight line function of samples No. 1, No. 2 and No. 3 are 0.304, 0.1846 and 0.508 respectively), it can be judged that the relative anticoagulant activity of low molecular weight heparin in the three samples is No. 3> No. 1> No. 2.
[0087] Comparison Example
[0088] The three sample plasmas in Example 1 were simultaneously treated with the Anti-Xa assay kit (Cat. No. 0020302600) purchased from Werfen Company, and the reagent bottles were inverted and mixed before use according to the operating requirements of the instructions in the kit, and then the Factor Xa reagent bottle and the color substrate reagent bottle were respectively placed in the ACL TOP 700 instrument, and after waiting for the instrument to recognize, the sample to be tested was placed in the detection area, the detection item Anti-Xa was selected, and "Run" was clicked to detect the anticoagulant activity of low molecular weight heparin in the sample. The results are shown in Table 1.
[0089] Table 1 Anticoagulant activity of low molecular weight heparin detected by Anti-Xa kit
[0090]
[0091] As can be seen from Table 1, the results of the anticoagulant activity of low molecular weight heparin in samples No. 1, No. 2, and No. 3 using the Anti-Xa kit are: No. 3> No. 1> No. 2, which is consistent with the results of judging the relative anticoagulant activity of low molecular weight heparin in multiple samples by k value in the method of Example 1. It can be seen that the method of Example 1 using k value to judge the relative anticoagulant activity of low molecular weight heparin in multiple samples is reliable.
[0092] Reference example
[0093] In this reference example, the sample used is a plasma sample obtained by blood draw and centrifugation from a patient who is known to be given oral rivaroxaban tablets for anticoagulation therapy 4 hours after medication.
[0094] According to the method in Example 1, the sample was tested.
[0095] The results are as follows Figure 2 The fitted straight line function is y = -0.0977x + 44.757 (R 2 =0.6166), presenting an irregular curve in the plane rectangular coordinate system. It can be seen that R 2 <0.90, so it can be found that
[0096] The method of Example 1 cannot be used to detect and determine the relative anticoagulant activity of rivaroxaban in multiple samples, but can be used to determine the relative anticoagulant activity of low molecular weight heparin in multiple samples.
[0097] Example 2
[0098] In this example, the components and preparation method of the kit used to detect the anticoagulant activity of low molecular weight heparin in a sample are the same as those in Example 1.
[0099] In this embodiment, the samples used are the same as those in Embodiment 1 (ie, Sample No. 1, Sample No. 2, and Sample No. 3 in Embodiment 1).
[0100] The specific operation of detecting the anticoagulant activity of low molecular weight heparin in the sample is the same as that in Example 1, except that the incubation time in step 2) is 8 min, 14 min, 21 min, and 28 min (10 min, 15 min, 20 min, and 30 min in Example 1).
[0101] The fitted straight line is as follows Figure 3 shown.
[0102] like Figure 3 As shown in the figure, when the points of the incubation time of 8min, 14min, 21min, 28min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the linear function fitted by sample No. 1 is y=0.3026x+26.53(R 2 =0.9901); the linear function of sample 2 is y=0.1945x+28.772(R 2 =0.9814); the linear function of sample 3 is y=0.5108x+30.233(R 2 =0.9949).
[0103] It can be seen that when the points of the incubation time of 8min, 14min, 21min, 28min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the R values of the linear function fitted by samples 1, 2, and 3 are 2 The values all satisfy R 2 >0.95, so according to the k value (the k values of the fitting straight line function of samples No. 1, No. 2, and No. 3 are 0.3026, 0.1945, and 0.5108, respectively), it can be judged that the relative anticoagulant activity of low molecular weight heparin in the three samples is No. 3> No. 1> No. 2. This is consistent with the judgment result in Example 1; and the difference between the k values obtained in this embodiment and in Example 1 is small, indicating that selecting different incubation time points has consistent experimental effects.
[0104] Example 3
[0105] In this example, the components and preparation method of the kit used to detect the anticoagulant activity of low molecular weight heparin in a sample are the same as those in Example 1.
[0106] In this embodiment, the samples used are plasma samples obtained by drawing blood 4 hours after subcutaneous injection of low molecular weight heparin (samples No. 4 and 5 are enoxaparin sodium, and sample No. 6 is dalteparin sodium) and centrifuging the blood to obtain the plasma samples.
[0107] In this embodiment, except that the incubation time in step 2) is 11 min, 16 min, and 22 min (10 min, 15 min, 20 min, and 30 min in embodiment 1), the specific operation of detecting the anticoagulant activity of low molecular weight heparin in the sample is the same as that in embodiment 1.
[0108] The fitted straight line is as follows Figure 4 shown.
[0109] like Figure 4 As shown in the figure, when the points of the incubation time of 11min, 16min, 22min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the linear function fitted by sample No. 4 is y=0.4302x+26.973(R 2 =0.9833); the linear function of sample No. 5 is y=0.4615x+28.062(R 2 =0.0.9926); the linear function fitted by sample 6 is y=0.2016x+26.273(R 2 =0.9763).
[0110] It can be seen that when the points of the incubation time of 11min, 16min, and 22min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the R values of the linear function fitted by samples 4, 5, and 6 are 2 The values all satisfy R 2 >0.95, so according to the size of k value (the k values of the fitting straight line function of samples No. 4, No. 5 and No. 6 are 0.4302, 0.4615 and 0.2016 respectively), it can be judged that the relative anticoagulant activity of low molecular weight heparin in the three samples is No. 5> No. 4> No. 6.
[0111] At the same time, the three plasma samples were subjected to Anti-Xa activity assay according to the method in the control example to detect the anticoagulant activity of low molecular weight heparin in the samples. The results are shown in Table 2.
[0112] Table 2 Anticoagulant activity of low molecular weight heparin detected by Anti-Xa kit
[0113]
[0114] As can be seen from Table 2, the results of the anticoagulant activity of low molecular weight heparin in samples No. 4, No. 5, and No. 6 using the Anti-Xa kit are No. 5> No. 4> No. 6, which is consistent with the results of judging the relative anticoagulant activity of low molecular weight heparin in multiple samples by k value in the method of Example 3. It can be seen that the method of Example 3 using k value to judge the relative anticoagulant activity of low molecular weight heparin in multiple samples is reliable.
[0115] Example 4
[0116] In this example, the components and preparation method of the kit used to detect the anticoagulant activity of low molecular weight heparin in a sample are the same as those in Example 1.
[0117] In this embodiment, sample No. 7 used is a plasma sample obtained by drawing blood 4 hours after subcutaneous injection of low molecular weight heparin (enoxaparin sodium) and centrifuging it; this patient was continuously treated with enoxaparin sodium from day 1 to day 3, and the method of the present invention was used to continuously monitor the anticoagulant activity of low molecular weight heparin.
[0118] In this embodiment, except that the incubation time in step 2) is 13 min, 17 min, 23 min, and 29 min (10 min, 15 min, 20 min, and 30 min in Example 1), the specific operation of detecting the anticoagulant activity of low molecular weight heparin in the sample is the same as that in Example 1.
[0119] The fitted straight line is as follows Figure 5 shown.
[0120] like Figure 5 As shown in the figure, when the points of the incubation time of 13min, 17min, 23min, 29min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the linear function fitted by the sample on the first day is y=0.4388x+25.855 (R 2 =0.9934); the linear function of the sample fitting on the second day is y=0.6704x+27.232(R 2 =0.9982); the linear function of the sample fitting on the third day is y=0.6248x+25.016 (R 2 =0.998).
[0121] It can be seen that when the points of the incubation time of 13min, 17min, 23min, and 29min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the R of the linear function fitted by sample No. 7 on the 1st day, the 2nd day, and the 3rd day is 2 The values all satisfy R 2 >0.95, therefore, according to the size of the k value (the k values of the fitting straight line function of sample No. 7 from the 1st day to the 3rd day are 0.4388, 0.6704, and 0.6248, respectively), it can be judged that the relative anticoagulant activity of the low molecular weight heparin in sample No. 7 for 3 days is the 2nd day > the 3rd day > the 1st day, that is, the anticoagulant activity of the low molecular weight heparin in the plasma of the same patient can be continuously monitored according to the k value obtained by the method of the present invention.
[0122] Example 5
[0123] In this example, the components and preparation method of the kit used to detect the anticoagulant activity of low molecular weight heparin in a sample are the same as those in Example 1.
[0124] In this embodiment, the sample used is the same as that of Embodiment 4 (ie, sample No. 7 in Embodiment 4).
[0125] In this embodiment, except that the incubation time in step 2) is 14 min, 18 min, 25 min (10 min, 15 min, 20 min, 30 min in embodiment 1), the specific operation of detecting the anticoagulant activity of low molecular weight heparin in the sample is the same as that in embodiment 1.
[0126] The fitted straight line is as follows Figure 6 shown.
[0127] like Figure 6 As shown in the figure, when the points of the incubation time of 14min, 18min, 25min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the linear function fitted by the sample on the first day is y=0.4016x+26.436(R 2 =0.9993); the linear function of the sample fitting on the second day is y=0.6516x+26.853 (R 2 =0.9992); the linear function of the sample fitting on the third day is y=0.6081x+25.347(R 2 =0.989).
[0128] It can be seen that when the points of the incubation time of 14min, 18min, and 25min and the corresponding anticoagulation test seconds in the plane rectangular coordinate system are used to fit a straight line, the R of the linear function fitted by sample No. 7 on the 1st, 2nd, and 3rd days is 2 The values all satisfy R 2 >0.95, therefore, according to the size of the k value (the k values of the fitting straight line function of sample No. 7 from the 1st day to the 3rd day are 0.4016, 0.6516, and 0.6081, respectively), it can be judged that the relative anticoagulant activity of the low molecular weight heparin in sample No. 7 for 3 days is the 2nd day > the 3rd day > the 1st day, that is, the anticoagulant activity of the low molecular weight heparin in the plasma of the same patient can be continuously monitored according to the k value obtained by the method of the present invention.
[0129] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A kit for detecting the relative anticoagulant activity of low molecular weight heparin in a sample, the kit comprising reagent 1 and reagent 2, in: The reagent 1 comprises the following components: Activator: 20-100 mg / L; Phospholipids: 0.5-2.0 g / L; Stabilizer: 0.5~2.0g / L; Buffer: 20~100mmol / L; Reagent 2: CaCL 2 Solution: 0.015~0.025mol / L.
2. The kit according to claim 1, Features: The activator is selected from at least one of kaolin, silica gel and ellagic acid, preferably ellagic acid; The phospholipid is cephalin derived from rabbit brain or bovine brain or artificially synthesized lecithin; The stabilizer is one or both of bovine serum albumin and polyethylene glycol with a molecular weight of 6000-20000; The buffer is Tris-HCL buffer.
3. The kit according to claim 1 or 2, Features: The kit also includes a preservative; The final concentration of the preservative in the reagent 1 is 0.5-1.0 g / L; The preservative is proclin 300 and / or sodium azide.
4. A method for detecting the relative anticoagulant activity of low molecular weight heparin in a sample, the method comprising the following steps: 1) adding at least two samples into a plurality of reaction cups respectively, and then adding reagents into each reaction cup and incubating them together; in, The incubation time of different reaction cups is at least three selected from 5 min-30 min; 2) After the incubation is completed, reagent 2 is added to the reaction cup to trigger the coagulation process, and the time required for plasma coagulation is measured to obtain the anticoagulation test seconds under different incubation times; 3) Construct a rectangular coordinate system with the incubation time as the horizontal axis and the anticoagulation test seconds as the vertical axis; Mark the points of the different incubation times described in step 1) and the corresponding anticoagulation test seconds described in step 2) in the plane rectangular coordinate system, and fit the marked points into a straight line in the plane rectangular coordinate system; If the function of the straight line y = kx + b R 2 >0.95, the relative anticoagulant activity of the low molecular weight heparins in the multiple samples is determined according to the k value of the linear function: the linear function with a larger k value corresponds to a sample with a higher anticoagulant activity of the low molecular weight heparin.
5. The method according to claim 4, Features: In step 1), the incubation temperature is 35°C-38°C, preferably 37°C; In step 1), in each reaction cup, the volume ratio of the sample to the reagent 1 is 1:(1-3), preferably 1:1; In step 2), in each reaction cup, the volume ratio of the sample to the second reagent is 1:(1-3), preferably 1:
1.
6. The method according to claim 5, Features: In step 1), the different incubation times are three; Preferably, the three incubation times are at least two selected from the three ranges of 5 min-10 min, 10 min-20 min, and 20 min-30 min.
7. The method according to any one of claims 4 to 6, Features: In step 1), the different incubation times are 11 min, 16 min, and 22 min; or In step 1), the different incubation times are 14 min, 18 min, and 25 min.
8. The method according to any one of claims 4 to 6, Features: In step 1), the number of different incubation times is four; Preferably, the four incubation times are at least two selected from the three ranges of 5 min-10 min, 10 min-20 min, and 20 min-30 min.
9. The method according to any one of claims 4 to 6, Features: In step 1), the different incubation times are 10 min, 15 min, 20 min, and 30 min; or: In step 1), the different incubation times are 8 min, 14 min, 21 min, and 28 min; or: In step 1), the different incubation times are 13 min, 17 min, 23 min, and 29 min.
10. The method according to any one of claims 4 to 6, Features: In step 1), the number of different incubation times is five; Preferably, the five incubation times are at least two selected from the three ranges of 5 min-10 min, 10 min-20 min, and 20 min-30 min.
